the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02674607

Enrollment

Registered

2016-02-04

Start date

2015-10-31

Completion date

2017-10-31

Last updated

2017-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Beta Thalassemia Major

Brief summary

The aim of this study is to evaluate the possible immunologic effects of spirulina in children with beta thalassemia.

Interventions

DIETARY_SUPPLEMENTSpirulina

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

4 Years to 18 Years

Healthy volunteers

Yes

Inclusion criteria

* children with thalassemia major

Exclusion criteria

* children with other chronic hemolytic anemias

Design outcomes

Primary

Measure	Time frame
cluster of differentiation (CD4/CD25) ratio	3 months
cluster of differentiation (CD33/CD11b/Lin) ratio	3 months
serum immunoglobulins levels	3 months
serum levels of interferon gamma	3 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026